Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.12 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: bardoxolone methyl, omaveloxolone | 1.00 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 55 Parkinson's papers of 1,732 | 0.47 |
| pathways Reactome | 17 pathways; mostly protein handling | 0.90 |
No case: the score is under the bar. Receipt 2342
Sealed predictions
- NFE2L2 in dopamine neurons, braak-0.08 (p 0.842) → +0.37 (p 0.334)receipt 2350
Swarm cases
receipt 2350: NFE2L2 in dopamine neurons, braak
- power
- full sample +0.14 (p 0.579, n 18), 95% CI -0.35 to +0.57. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.15 (p 0.555, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.13 (p 0.597, n 18). could be the mix.
- skeptic
- leave-one-out range +0.05 to +0.27, sign flips 0; without severely affected donors +0.14 (p 0.579, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NFE2L2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts